CONSIDERATIONS TO KNOW ABOUT CP-866087

Considerations To Know About CP-866087

bortezomib will raise the stage or outcome of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Elevated flibanserin adverse results might arise if coadministered with a number of weak CYP3A4 inhibitors.Treatment causes peripheral neuropathy (predominantly sensory); on the other hand, circumstances of intense

read more